- $4.21bn
- $4.84bn
- $1.31bn
- 90
- 33
- 86
- 79
Annual income statement for Haemonetics, fiscal year end - March 30th, USD millions except per share, conversion factor applied.
2020 March 28th | 2021 April 3rd | 2022 April 2nd | 2023 April 1st | 2024 March 30th | |
|---|---|---|---|---|---|
| Period Length: | 52 W | 52 W | 52 W | 52 W | 52 W |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 988 | 870 | 993 | 1,169 | 1,309 |
| Cost of Revenue | |||||
| Gross Profit | 488 | 408 | 531 | 623 | 709 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 885 | 781 | 912 | 1,013 | 1,144 |
| Operating Profit | 103 | 89.7 | 80.8 | 156 | 165 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 87.2 | 72.9 | 63.6 | 141 | 152 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 76.5 | 79.5 | 43.4 | 115 | 118 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 76.5 | 79.5 | 43.4 | 115 | 118 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 76.5 | 79.5 | 43.4 | 115 | 118 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 2.56 | 1.64 | 1.63 | 2.74 | 3.35 |